Received Mar 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | IM |
| FLUX | INFLUENZA (SEASONAL) (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
has been experiencing injection site soreness for 7 months; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (has been experiencing injection site soreness for 7 months) in a female patient of an unknown age who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) for COVID-19 prophylaxis. Co-suspect product included non-company product Influenza vaccine (Flu) for an unknown indication. No Medical History information was reported. On 18-Sep-2024, the patient received dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Intramuscular use) 1 dosage form and dose of Influenza vaccine (Flu) (unknown route) 1 dosage form. On 18-Sep-2024, the patient experienced VACCINATION SITE PAIN (has been experiencing injection site soreness for 7 months). At the time of the report, VACCINATION SITE PAIN (has been experiencing injection site soreness for 7 months) had not resolved. No concomitant medication was reported. No treatment information was reported. This case was linked to US-MODERNATX, INC.-MOD-2025-783153 (E2B Linked Report).; Sender's Comments: US-MODERNATX, INC.-MOD-2025-783153:Invalid case multiple patients having similar events